Literature DB >> 12955465

Immunopathology of human T cell responses to skin, artery and endothelial cell grafts in the human peripheral blood lymphocyte/severe combined immunodeficient mouse.

Jordan S Pober1, Alfred L M Bothwell, Marc I Lorber, Jennifer M McNiff, Jeffrey S Schechner, George Tellides.   

Abstract

Blood vessels and their endothelial lining are major stimulators and targets of the rejection response. The immunological properties of human endothelial cells differ significantly from those of other species and new models are needed for proper study of human vessels in the transplant setting. We have employed the human peripheral blood lymphocyte/severe combined immunodeficiency (huPBL/SCID) mouse for this purpose. We describe here our results involving transplantation of human skin, human artery and cultured human endothelial cells. We also describe our more limited experience using porcine skin and artery transplantation to study human T cells responses to pig endothelium.

Entities:  

Mesh:

Year:  2003        PMID: 12955465     DOI: 10.1007/s00281-003-0135-1

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  25 in total

1.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

2.  Antibody to human leukocyte antigen triggers endothelial exocytosis.

Authors:  Munekazu Yamakuchi; Nancy C Kirkiles-Smith; Marcella Ferlito; Scott J Cameron; Clare Bao; Karen Fox-Talbot; Barbara A Wasowska; William M Baldwin; Jordan S Pober; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

3.  Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.

Authors:  Tai Yi; Deepak A Rao; Paul C Y Tang; Yinong Wang; Lisa A Cuchara; Alfred L M Bothwell; Christopher M Colangelo; George Tellides; Jordan S Pober; Marc I Lorber
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

Review 4.  The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance.

Authors:  Johannes Wedel; Hironao Nakayama; Nora M Kochupurakkal; Josephine Koch; Michael Klagsbrun; Diane R Bielenberg; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

Review 5.  Participation of blood vessel cells in human adaptive immune responses.

Authors:  Jordan S Pober; George Tellides
Journal:  Trends Immunol       Date:  2011-10-24       Impact factor: 16.687

Review 6.  Noncognate function of B cells in transplantation.

Authors:  Samuel J Balin; Jeffrey L Platt; Marilia Cascalho
Journal:  Transpl Int       Date:  2009-01-16       Impact factor: 3.782

7.  Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model.

Authors:  Jason D Roh; Gregory N Nelson; Matthew P Brennan; Tamar L Mirensky; Tai Yi; Tyrone F Hazlett; George Tellides; Albert J Sinusas; Jordan S Pober; W M Saltzman; Themis R Kyriakides; Christopher K Breuer
Journal:  Biomaterials       Date:  2007-12-27       Impact factor: 12.479

8.  Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.

Authors:  Chen Wang; Tai Yi; Lingfeng Qin; Roberto A Maldonado; Ulrich H von Andrian; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

Review 9.  Use of humanized severe combined immunodeficient mice for human vaccine development.

Authors:  Gloria C Koo; Aisha Hasan; Richard J O'Reilly
Journal:  Expert Rev Vaccines       Date:  2009-01       Impact factor: 5.217

10.  T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase.

Authors:  Kian Peng Koh; Yinong Wang; Tai Yi; Stephen L Shiao; Marc I Lorber; William C Sessa; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.